Directly from the horses mouth so to speak .. from PharmaFrontiers:

TovaxinTM is a novel T-cell therapeutic vaccine that parallels the concept of autologous cancer vaccines.

Instead of modifying cancerous cells, TovaxinTM consists of attenuated autoreactive T cells.

Attenuation of these cells during the vaccine production process renders the cells non-replicating but viable and causes them to elicit an immune response when injected subcutaneously into the patient.

This immune response is directed against T cells within the patient that are self-reactive with myelin.

This immune response, directed against a specific subset of autoreactive T cells, greatly reduces the number of these autoreactive cells in MS patients.

TovaxinTM has considerable potential because it attacks the underlying cause of MS rather than just addressing its symptoms.

Additionally, an article about the current testing underway regarding Tovaxin was discussed over at Reuters: Promising Multiple Sclerosis treatments on the way

Also Mentioned In: PharmaFrontiers Provides Update, Financial Results

And the Initial Buyout Info is here: PharmaFrontiers Completes Acquisition of Multiple Sclerosis Cell Therapy Developer Opexa Pharmaceuticals, inc.

You may ask what Tovaxin has to do with Stem Cell Research, in truth, not that much currently. However, may tests are being done in what could be seen as this related field. Since so many are looking for news regarding Multiple Sclerosis within the stem cell field, it seems suitable to at least get the articles we have here listed.

Effectively its more information consolidation in a related field from a high profile stem cell company. Will post more here as we gather more ....